Dr. Dan Costin, MD

Dr. Costin practices at White Plains Hospital in White Plains, New York, part of Montefiore Einstein.

Dr. Costin's NPI, 1033103155, was assigned on September 2, 2005. Dr. Costin graduated from University of California (San Francisco) School of Medicine in 1987. Dr. Costin holds New York license 185812.

Dr. Costin's primary practice is White Plains Hospital, at Davis Ave at E Post Road, White Plains, NY 10601 in Westchester County. The practice phone is (914) 681-0600. Dr. Costin also practices at White Plains Hospital, 41 E Post Rd, White Plains, NY 10601.

Dr. Costin's primary practice is White Plains Hospital in White Plains, New York, part of Montefiore Einstein. Dr. Costin is also affiliated with Montefiore Einstein Hospital-Moses Campus. The medical group on file is Cancer & Blood Specialists of New York. Dmand AI also links Dr. Costin to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Costin practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Costin's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Costin is licensed in New York.

CMS data shows 1,589 Medicare services from Dr. Costin across 10 procedure codes in 2024, for 372 Medicare patients. Medicare paid $115,300 for them. Every service was in an office.

CMS counts 372 Medicare patients who saw Dr. Costin in 2024. The largest group is 75 to 84, with 175 patients. 75% of them have anxiety, and 75% have cancer. 5% are also on Medicaid. Their average risk score is 1.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Costin's median patient age at 75, with 59% women.

In 2024, Dr. Costin wrote 579 Medicare Part D claims for 124 patients. 74% of them were for generic drugs. CMS names the drug for 381 of them, across 18 drugs with 11 or more claims each, at $724,706 in total drug cost. In 2023, CMS named 285 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Costin for performance year 2024, reported as part of a group. Dr. Costin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Costin as offering telehealth.

Dmand AI links 5 papers to Dr. Costin, published from 2010 to 2024. Dr. Costin's most frequent co-authors are Nabil Adra, MD, Anjali Anil Bharne, MD and Ioana R. Bonta, MD.

Dmand AI links Dr. Costin to 10 clinical trials, 3 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Fallopian Tube Diseases, Fallopian Tube Neoplasms and Carcinoma, Bronchogenic. National Cancer Institute (NCI) sponsors the most, 9. Open Payments lists research payments to Dr. Costin that name 1 trial.

CMS Open Payments shows 18 general payments to Dr. Costin from 7 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 90% of the total. Janssen Pharmaceuticals, Inc paid the most, $79. It also lists 2 research payments totaling $1,677 in 2018, naming 1 clinical trial.

Dr. Costin graduated from University of California (San Francisco) School of Medicine in 1987.